Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

795 results about "Colonization" patented technology

Colonization (or colonisation) is a process by which a central system of power dominates the surrounding land and its components. Colonization refers strictly to migration, for example, to settler colonies in America or Australia, trading posts, and plantations, while colonialism to the existing indigenous peoples of styled "new territories". Colonization was linked to the spread of tens of millions from Western European states all over the world. In many settled colonies, Western European settlers eventually formed a large majority of the population after killing or driving away indigenous peoples. Examples include the Americas, Australia and New Zealand. These colonies were occasionally called 'neo-Europes'. In other places, Western European settlers formed minority groups, which often used more advanced weaponry to dominate the people initially living in their places of settlement.

Probiotic, lactic acid-producing bacteria and uses thereof

InactiveUS20060099197A1Good curative effectMitigating deleterious side-effectsAntibacterial agentsBiocideMicrobial agentAnti fungal
The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid—producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.
Owner:GANEDEN BIOTECH

Probiotic, lactic acid-producing bacteria and uses thereof

InactiveUS7708988B2Good curative effectMitigating deleterious side-effectsAntibacterial agentsBiocideDiseaseMicrobial agent
The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.
Owner:GANEDEN BIOTECH

Production method of pig feed additive containing traditional Chinese medicine and active probiotics

The invention discloses a production method of a pig feed additive containing traditional Chinese medicine and active probiotics, which comprises the steps of: respectively conducting single-spawn strain quantity expanding culture to the parent strains of active probiotics for pigs; mixing equiponderant first-order seed liquid of all kinds of active probiotics for pigs, inoculating the liquid into seed tank culture mediums for multi-spawn mixed culture and then inoculating the liquid into traditional Chinese medicine liquid culture mediums for primary traditional Chinese medicine fermentation; and mixing multi-spawn mixed traditional Chinese medicine fermentation liquid with corn cob meal with the same volume to obtain solid fermented seeds and then inoculating the seeds into traditional Chinese medicine solid culture mediums for secondary traditional Chinese medicine fermentation. By implementing the embodiment of the invention, the strain activity of the active probiotics in the pigfeed additive and the colonization performance in intestinal canals can be greatly improved, the produced pig feed additive is rich in traditional Chinese medicine compositions, the effect of active compositions which take a pharmacological effect in the traditional Chinese medicine compositions can be fully exerted, the body strengthening and disease curing performance and the growth promoting performance of the pig feed additive are improved and therefore the use of antibiotics can be fully avoided.
Owner:华林(辽宁)生物科技有限公司

Systems and methods that kill infectious agents (bacteria) without the use of a systemic anti-biotic

A medical product is provided that is selected from at least one of, nasal cannulas, oxygen masks, wound dressings, bandages, band aids, catheters, endotrachial tubes, condoms, surgical and other gloves, sheaths for endoscopy probes, and medical products that physically touch the body. A coating is included with at least one of, a non-antibiotic, antimicrobial and / or antiviral substance that prevents further local, non-systemic, colonization of infections.
Owner:BLACK MICHAEL DARRYL +1

Probiotic, lactic acid-producing bacteria and uses thereof

InactiveUS20080233104A1Good curative effectMitigating deleterious side-effectsAntibacterial agentsAntimycoticsDiseaseMicrobial agent
The present invention discloses compositions and methodologies for the utilization of probiotic organisms in therapeutic compositions. More specifically, the present invention relates to the utilization of one or more species or strains of lactic acid-producing bacteria, preferably strains of Bacillus coagulans, for the control of gastrointestinal tract pathogens, including antibiotic-resistant gastrointestinal tract pathogens, and their associated diseases by both a reduction in the rate of colonization and the severity of the deleterious physiological effects of the colonization of the antibiotic-resistant pathogen. In addition, the present invention relates to the utilization of therapeutic compounds comprised of lactic acid-producing bacteria and anti-microbial agents such as antibiotics, anti-fungal compounds, anti-yeast compounds, or anti-viral compounds. The present invention also discloses methodologies for: (i) the selective breeding and isolation of probiotic, lactic acid-producing bacterial strains which possess resistance or markedly decreased sensitivity to anti-microbial agents (e.g., antibiotics, anti-fungal agents, anti-yeast agents, and anti-viral agents); and (ii) treating or preventing bacteria-mediated infections of the gastrointestinal tract by use of the aforementioned probiotic bacterial strains with or without the concomitant administration of antibiotics. While the primary focus is on the treatment of gastrointestinal tract infections, the therapeutic compositions of the present invention may also be administered to buccal, vaginal, optic, and like physiological locations.
Owner:GANEDEN BIOTECH

Method for preparing cow feed additive containing traditional Chinese medicine active probiotics

The invention discloses a method for preparing a cow feed additive containing traditional Chinese medicine active probiotics, comprising the following steps: respectively carrying out amplification culture of the strain number of a single bacterial specie on original strains of active probiotics for cows; mixing primary seed liquors of active probiotics for cows with same weight, inoculating the mixture in a seed tank medium to carry out multiple-strain mixed culture, then inoculating in a traditional Chinese medicine liquid medium to carry out a primary traditional Chinese medicine fermentation; and mixing the multiple-strain mixed traditional Chinese medicine fermentation liquor with isometric cob powder to obtain solid fermentation seeds, and then inoculating in a traditional Chinese medicine solid medium to carry out a secondary traditional Chinese medicine fermentation. According to the invention, the strain activity and colonization performance in the intestinal tracts of activeprobiotics in the cow feed additive are improved greatly, the prepared cow feed additive is rich in traditional Chinese medicine components, the active components with pharmacological effects in the traditional Chinese medicine components fully play the role, thus the performances of strengthening the body, treating diseases and promoting growth of the cow feed additive are improved, and furthermore completely displace antibiotics.
Owner:辽宁后金生物科技有限公司

Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository

InactiveUS20080274162A1Reduction rate of colonizationBiocideGogglesDiseaseBacteroides
This invention is a probiotic composition using the delivery mode of a rectal suppository for the treatment and relief of symptoms of urogenital infections including prostatitis. This invention is unique in both mode of delivery and in enabling the treatment of such urogenital infections as prostatitis. The present invention discloses compositions, methodologies, and delivery mode for the utilization of probiotic organisms in therapeutic compositions for treatment and relief from the symptoms of urogenital infections by maintaining and restoring normal flora in humans. The composition includes one or more bacteria selected from the genus Lactobacillus. More specifically, the invention relates to the utilization of one or more species or strains of Lactobacillus producing bacteria for the control of urinary tract bacteria and pathogens, including antibiotic-resistant urinary tract pathogens, and their associated diseases by both a reduction in the rate of colonization of the infection and pathogens. The method for treatment and relief from symptoms includes administration via a rectal suppository with a safe and effective amount of the composition. The delivery mode for administering the probiotic is via a rectal suppository. The delivery through the rectum provides an optimum method of transmission of the treatment.
Owner:NESSA JEFFREY +1

Capsular polysaccharide adhesin antigen, preparation, purification and use

A substantially pure capsular exopolysaccharide adhesin of coagulaso-negative staphylococcal strains, and a general method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and mono-clonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymeric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by noso-comial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products